Latest Entry: American Pravda and New York's Sixth Crime Family     Latest Comments: Talk Back Here

« Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? | Main | Threat of east-west split looms in Ukraine »

November 29, 2004

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

Topics: Clinical Pharmacology

Abstract Review. Neurology. 2004 Jun 8;62(11):2038-43. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA; Natalizumab Multiple Sclerosis Trial Group. St. Michael's Hospital, Toronto, Ontario, Canada. oconnorp@smh.toronto.on.ca

Relapses in multiple sclerosis (MS) can cause significant neurologic disability. Natalizumab (Antegren) is a humanized anti-alpha4-integrin antibody that inhibits the trafficking of leukocytes across endothelium by blocking binding of alpha4beta1-integrin to vascular cell adhesion molecule-1.

The objective of the study was to assess the effects of a single dose of IV natalizumab administered soon after the onset of MS relapses.

METHODS: In this randomized, double-blind, multicenter trial, the effects of a single dose of IV natalizumab administered soon after the onset of MS relapses were assessed. MS patients (n = 180) in acute relapse were randomly assigned to receive a single dose of natalizumab 1 or 3 mg/kg or placebo and were followed for 14 weeks. RESULTS: There was no difference in Expanded Disability Status Scale (EDSS) score change over time between treatment and placebo groups. In all three groups, approximately half of patients showed EDSS improvement after 2 weeks, rising to 67% by 8 weeks. EDSS improved by a mean value of 0.8 point at week 1, 1.2 points at week 4, and 1.6 points at week 8 in the natalizumab group compared with EDSS improvement of 1.0 point at week 1, 1.6 points at week 4, and 1.6 points at week 8 in the placebo group. A significant decrease in Gd-enhancing lesion volume was seen in both active treatment groups at weeks 1 and 3 compared with placebo.

CONCLUSIONS: A single dose of IV natalizumab did not hasten clinical recovery after relapse, although a significant decrease in Gd-enhancing lesion volume was observed at 1 and 3 weeks after treatment. These MRI findings are consistent with prior studies of natalizumab and support its further investigation as an agent for the treatment of MS.
PMID: 15184611

Posted by Hyscience at November 29, 2004 9:47 AM



Articles Related to Clinical Pharmacology: